GlassScriptPhysician profile
Erich J Conrad
NPI 1861414633
$8,572.70
in general payments reported to CMS, 2019-2025
27 companies · $1,772 in 2025
The $1,772 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,718 · 2020: $722 · 2021: $1,126 · 2022: $622 · 2023: $1,535 · 2024: $1,077 · 2025: $1,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,322 · Education: $61.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,322.44 |
| Education | $61.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,525.47 | 2019-2025 | Spravato, Invega, Invega Sustenna |
| Alkermes, INC. | $1,508.51 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $1,097.32 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $627.64 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $550.14 | 2019-2025 | Ingrezza |
| Abbvie INC. | $512.28 | 2021-2025 | Vraylar |
| Lundbeck LLC | $432.44 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $370.00 | 2019-2021 | |
| Allergan, INC. | $366.16 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $298.91 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $179.44 | 2023-2025 | Fanapt, Hetlioz |
| Indivior INC. | $164.01 | 2023-2024 | Perseris |
| Supernus Pharmaceuticals, INC. | $147.36 | 2024-2025 | Qelbree |
| Axsome Therapeutics, INC. | $143.30 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $97.45 | 2021-2024 | Caplyta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $90.56 | 2019-2021 | |
| Shire North American Group INC | $68.10 | 2019 | |
| Jazz Pharmaceuticals INC. | $66.60 | 2020 | |
| Tris Pharma INC | $65.72 | 2023-2024 | Dyanavel Xr |
| Avanir Pharmaceuticals, INC. | $56.78 | 2019 | |
| Ironshore Pharmaceuticals INC. | $45.17 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $38.63 | 2025 | Cobenfy |
| Janssen Scientific Affairs, LLC | $35.50 | 2019 | |
| Brainsway USA INC | $28.23 | 2023 | |
| Bioxcel Therapeutics, INC. | $22.09 | 2023 | Igalmi |
| Luye Pharma (USA) LTD. | $19.04 | 2025 | Erzofri Extended-Release |
| Braeburn INC. | $15.85 | 2024 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erich Conrad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.